SynthesisFrontiers in immunology2022

Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis.

Shuang Fan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.